Edgewise Therapeutics (EWTX) grants director 16,377 stock options

Rhea-AI Filing Summary

Edgewise Therapeutics director Jonathan D. Root received a grant of stock options to acquire 16,377 shares of common stock on June 5, 2026. The options have an exercise price of $35.5900 per share and expire on June 5, 2036. According to the grant terms, 100% of the options vest on the earlier of June 5, 2027 or the business day prior to the 2027 annual meeting of shareholders, and Root now directly holds options for 16,377 shares from this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider ROOT JONATHAN D

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	16,377	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 16,377 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 16377.0000 options Exercise price: $35.5900 per share Expiration date: 2036-06-05 +2 more

5 metrics

Stock options granted 16377.0000 options Grant to director Jonathan D. Root on 2026-06-05

Exercise price $35.5900 per share Exercise price of stock options granted on 2026-06-05

Expiration date 2036-06-05 Expiration date of the granted stock options

Vesting condition date 2027-06-05 100% vesting on earlier of 2027-06-05 or business day before 2027 annual meeting

Underlying shares 16377.0000 shares Common shares underlying the granted stock options

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vested

4 terms

Stock Option (Right to Buy) financial

"security_title shows "Stock Option (Right to Buy)" for the grant"

exercise price financial

"conversion_or_exercise_price set at 35.5900 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date is reported as 2036-06-05 for the options"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vested financial

"100% of the Stock Options Granted ... will become vested on the earlier of..."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/17/2026 - 04:25 PM Accepted by SEC EDGAR 07/17/2026 - 04:24 PM Learn about SEC filing dates

FAQ

What stock options were granted to Jonathan D. Root at Edgewise Therapeutics (EWTX)?

Jonathan D. Root received 16,377 stock options for Edgewise Therapeutics common stock on June 5, 2026. These options allow him to buy 16,377 shares at a $35.5900 exercise price and expire on June 5, 2036 if not exercised.

When do Jonathan D. Root’s Edgewise Therapeutics (EWTX) options vest?

All of the granted options vest 100% on the earlier of June 5, 2027 or the business day before Edgewise Therapeutics’ 2027 annual meeting of shareholders. No partial vesting schedule is described; the entire grant vests at that time.

What is the exercise price of the new Edgewise Therapeutics (EWTX) options?

The options have an exercise price of $35.5900 per share. This is the fixed price at which Jonathan D. Root may purchase Edgewise Therapeutics common stock under the grant from June 5, 2026 until their expiration on June 5, 2036.

How many Edgewise Therapeutics (EWTX) shares can be acquired through the new options?

The grant covers 16,377 underlying shares of Edgewise Therapeutics common stock. If fully vested and exercised at the $35.5900 exercise price, these options would permit purchase of exactly 16,377 shares, subject to the stated vesting and expiration terms.

Were Jonathan D. Root’s Edgewise Therapeutics (EWTX) options granted under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked as affirmed, and no footnote states the grant is under a trading plan. Based on this disclosure, the grant is presented as a compensation-related award rather than a pre-arranged trading plan transaction.

What is Jonathan D. Root’s reported holding from this Edgewise Therapeutics (EWTX) option grant?

After the transaction, the Form 4 shows 16,377 derivative securities held directly from this grant. These represent stock options for 16,377 underlying shares, subject to the vesting provision tied to June 5, 2027 or the 2027 annual meeting timing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROOT JONATHAN D

(Last) (First) (Middle)

1460 EL CAMINO REAL STE 100

(Street)

MENLO PARK CALIFORNIA 94025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.59	06/05/2026		A		16,377		06/02/2027(1)	06/05/2036	Common Stock	16,377	$0	16,377	D

Explanation of Responses:

1. 100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders.

	/s/ John R. Moore Attorney-in-Fact for Jonathan Root M.D.	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)